Full Press Release Details
Announces Second Quarter 2016
Financial Results and Recent Clinical Highlights
Wednesday, August 17th at 10:00 am ET
New York, NY and Cleveland, OH - August 16, 2016 -
Abeona Therapeutics Inc. (Nasdaq: ABEO) a clinical-stage biopharmaceutical company focused on delivering gene and plasma-based
therapies for life-threatening rare diseases, today announced financial results for the second quarter. The Company will provide
investors an update on recent and ongoing business activities and an overview of its 2Q16 financials on, Wednesday, August 17th,
at 10:00 am (Eastern). Interested parties are invited to participate in the call by dialing 877-269-7756 (toll free domestic)
or 201-689-7817 (international).
"The second fiscal quarter of 2016 brought significant
advancements in our goal of building a strong leadership position in the development of innovative therapies for rare diseases,"
stated Steven H. Rouhandeh, Executive Chairman. "We are excited about the initial biopotency signals seen in our Sanfilippo
Type A clinical trial, and are looking forward to advancing multiple important new therapeutic candidates for the treatment of
epidermolysis bullosa (EB), as announced last week. We thank our collaborators, shareholders and staff for their ongoing commitment
and support as we move these therapies further into clinical development."
Timothy J. Miller, Ph.D, stated, "Abeona achieved many
important regulatory and clinical milestones in the second quarter of 2016. The milestones include the dosing of the first patient
in our Phase 1/2 clinical trial with ABO-102 for patients with Sanfilippo syndrome type A, the FDA allowance of our Phase 1/2
clinical study in Sanfilippo syndrome type B (MPS IIIB), and, most recently, the European regulatory approval for our MPS IIIA
Phase 1/2 clinical study to be conducted at Cruces University Hospital in Bilbao, Spain. Additionally, we are excited about our
new collaboration with the EB Research Partnership, EB Medical Research Foundation and Stanford University to accelerate up to
three new promising EB product candidates toward commercialization."
Recent Abeona Operating Highlights
Second Quarter Summary Financial Results
About Abeona: Abeona Therapeutics
Inc. is a clinical stage company developing gene therapy and plasma-based therapies for severe and life-threatening rare genetic
diseases. Abeona's lead programs are ABO-102 (AAV-SGSH) and ABO-101 (AAV-NAGLU), adeno-associated virus (AAV) based gene therapies
for Sanfilippo syndrome (MPS IIIA and IIIB), respectively. We are also developing EB-101 (gene-corrected skin grafts) for recessive
dystrophic epidermolysis bullosa (RDEB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JBD); and ABO-301 (AAV-FANCC)
for Fanconi anemia (FA) disorder using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases.
In addition, Abeona is developing plasma protein therapies, including SDF Alpha (alpha-1 protease inhibitor) for inherited
COPD, using our proprietary SDF (Salt Diafiltration) ethanol-free process. For more information, visit www.abeonatherapeutics.com.
press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of
1933, as amended, and that involve risks and uncertainties. These statements include, without limitation, our plans for continued
development and internationalization of our clinical programs, that we are looking forward to advancing multiple
important new therapeutic candidates for the treatment of epidermolysis bullosa, that we plan to accelerate up to three new promising
EB product candidates toward commercialization, that encouraging signs of early biopotency had been observed in urinary and CSF
GAG (heparan sulfate) measurements as well as potential disease-modifying effects in the liver and spleen in our ABO-102 program,
management plans for the Company, and general business
outlook. These statements are subject to numerous risks and uncertainties, including but not limited to continued interest in
our rare disease portfolio, our ability to enroll patients in clinical trials, the impact of competition; the ability to develop
our products and technologies; the ability to achieve or obtain necessary regulatory approvals; the impact of changes in the financial
markets and global economic conditions; and other risks as may be detailed from time to time in the Company's Annual Reports on
Form 10-K and other reports filed by the Company with the Securities and Exchange Commission. The Company undertakes no obligations
to make any revisions to the forward-looking statements contained in this release or to update them to reflect events or circumstances
occurring after the date of this release, whether as a result of new information, future developments or otherwise.
Christine Berni-Silverstein
Vice President, Investor Relations
Abeona Therapeutics Inc
Vice President, Communications & Operations
Abeona Therapeutics Inc